**Table S1.** Linear regression models for analyzing independent variable's influence on total uEV levels

| Models | Regression coefficients | Std Error | P-value |
| --- | --- | --- | --- |
| Age | 23.29 | 68.15 | 0.734 |
| Diabetes | 472.65 | 3124.10 | 0.881 |
| Hypertension | -1563.98 | 2644.72 | 0.558 |

**Table S2.** Urinary levels of immune mediators in COVID-19 hospitalized patients and healthy controls

| Parameters (pg/μL) | HC n= 7 | Mild/Moderate (n=24) | Severe/Critical (n=12) | *P*-value |
|---|---|---|---|---|
| **Pro-inflammatory cytokines** | | | | |
| IL-1$\alpha$ | 1.1±0.9 | 2.9±3.7 | 3.3±3.5 | 0.5 |
| IL-1$\beta$ | 0.77±0.3 | 0.94±0.6 | 1.9±1.2 | **0.02[b, c]** |
| IL-4 | 0.26±0.2 | 0.21±0.15 | 1.04±1.02 | **0.0003[b, c]** |
| IL-5 | 10.0±4.6 | 9.7±5.2 | 8.0±4.6 | 0.51 |
| IL-6 | 0.33±0.31 | 2.5±6.0 | 177.6±456.2 | **0.0005[b, c]** |
| IL-7 | 10.3±6.3 | 8.0±6.0 | 14.6±4.9 | **0.02[c]** |
| IL-8 | 3.6±2.7 | 60.0±158.7 | 33.4±50.9 | 0.09 |
| IL-9 | 5.6±2.5 | 2.8±1.7 | 2.7±1.8 | **0.02[a, b]** |
| IL-13 | 0.17±0.06 | 0.27±0.48 | 0.28±0.14 | **0.02[c]** |
| IL-16 | 0.70±0.27 | 3.5±6.8 | 42.5±58.6 | **0.003[b, c]** |
| IL-17A | 2.3±0.7 | 2.2±1.7 | 7.0 ±8.8 | **0.04[c]** |
| IL-18 | 4.2±2.0 | 7.9±7.4 | 11.7±5.0 | **0.003[b]** |
| TNF-$\alpha$ | 8.3±0.8 | 14.0±13.5 | 13.8±7.6 | 0.3 |
| IFN-$\gamma$ | 13.4±3.3 | 23.3±25.7 | 67.4±52.8 | 0.05 |
| LIF | 7.2±3.6 | 9.6±6.7 | 53.2±50.3 | **0.03 [b]** |
| MIF | 53.3±18.3 | 190.1±387.4 | 555.2±589 | **0.01[c]** |
| **Anti-inflammatory cytokines** | | | | |
| IL-1Ra | 2856±2724 | 19806±14112 | 25212±11483 | **0.02[a,b]** |
| IL-2Ra | 57.3±15.5 | 86.3±136.5 | 73.4±54.0 | 0.9 |
| **Chemokines** | | | | |
| CCL-2 | 94.9±63.7 | 265.2±607 | 47074 ±30129 | **0.0001[b,c]** |
| CCL-3 | 0.15±0.1 | 1.1±2.1 | 2.8 ±3.9 | **0.03[b]** |
| CCL-4 | 3.3±2.1 | 1.3±1.7 | 2.5±2.8 | **0.04 [a]** |
| CCL-5 | 477.9±825 | 9.1±12.8 | 15.9±14.7 | **0.03 [a]** |
| CCL-11 | 14.9±4.0 | 11.7±15.6 | 134.6±175.1 | **0.02[c]** |
| CXCL-9 | 60.2±44.5 | 236.8±842.4 | 215.2±424.6 | 0.06 |
| CXCL-10 | 3542±3383 | 5215±8783 | 92838±104934 | **0.002[b,c]** |
| CXCL-12 | 196408±320252 | 12485±46187 | 12645±16856 | **0.04[a]** |

**Supplementary Table S2.** (cont)

| Parameters (pg/μL) | HC n= 7 | Mild/Moderate (n=24) | Severe/Critical (n=12) | *P*-value |
|---|---|---|---|---|
| **Growth factors and others** | | | | |
| PDGF-BB | 6.7±1.9 | 5.2±2.1 | 5.7±3.5 | 0.25 |
| FGF-B | 8.7±1.6 | 9.6±3.3 | 15.7±9.3 | **0.008**[b,c] |
| M-CSF | 159.4±128.1 | 230.3±224.5 | 444.1±259.6 | **0.01**[b,c] |
| SCF | 10.4±.6.9 | 39.8±69.8 | 104.5±158.8 | 0.06 |
| SCGF-β | 56.3±58.8 | 112.5±89.0 | 82.7±88.6 | 0.23 |
| HGF | 21.6±13.4 | 26.5±23.5 | 64.5±51.9 | 0.15 |
| TRAIL | 1.1±0.8 | 1.3±1.1 | 2.1±2.3 | 0.91 |
| CTAcK | 7.3±2.7 | 5.6±6.0 | 15.44±13.5 | **0.01**[a,c] |

Data is presented as n (%) or mean ± standard deviation. P-values were calculated using ANOVA test and post-test Turkey or Kruskal Wallis test post-test Dunn' (a, HC *vs* Mild/Moderate; b, HC *vs* Severe/Critical; c, Mild/Moderate *vs* Severe/Critical) and were considered statistically significant when p <0.05 (in bold).